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The nitric oxide (NO)-sensitive guanylyl cyclase plays a
key role in diverse signalling pathways by catalysing the
biosynthesis of the messenger molecule cGMP. To date,
two isoforms of the enzyme (α1β1 and α2β1) are known,
both of which contain a prosthetic heme group bound to
the histidine 105 of the β1 subunit. The α1β1 isoform is
ubiquitously expressed and is considered to be soluble,
whereas the α2β1 isoform is mainly expressed in brain and
is located to the membrane via interaction with PSD-95.
The three-dimensional structure of NO-sensitive guanylyl
cyclase has not been solved. Yet, by sequence comparison
the subunits are generally divided into three domains. An
N-terminal regulatory domain, a central domain postu-
lated to be involved in dimerization and a C-terminal cat-
alytic domain. For catalytic activity dimerization of the α
and β subunit is mandatory, but until recently the regions
involved in the interaction were unknown.
By coprecipitation of several deletion mutants of the α1
and β1 subunit, expressed in Sf9-cells, we have mapped
the α1 dimerization domain to amino acids 61-462.
Within this region, we identified two binding sites. One,
as postulated, covering the central amino acids 367-462,
the other, quite unexpectedly, located in the N terminus
of the α1-subunit (amino acids 61-128). By itself neither
region was sufficient to mediate full dimerization. Of the
β1 subunit the N-terminal and central amino acids 1-385
exhibited wt-like binding to the identified α1 domain. To
further characterize the short, but stable, dimeric NO-sen-
sitive guanylyl cyclase we purified the mutant from Sf9-
cells and analysed heme-coordination and binding of NO
in spectrophotometric measurements. The dimeric state
of the mutant was confirmed by gelfiltration analysis.
As β1 is the binding partner for both the α1 and α2 subunit,
we reasoned that dimerization of the α2β1 isoform must
be mediated by parts of the α2 subunit homologous to theα1 dimerization domain. Accordingly, we cloned the
respective sequences of α2 (amino acids 76-501) and ana-
lysed binding of the mutant to the N-terminal and central
regions of β1.
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